Results 1 to 10 of about 293,272 (302)

How CAR T Cells Breathe

Cells, 2022
The manufacture of efficacious CAR T cells represents a major challenge in cellular therapy. An important aspect of their quality concerns energy production and consumption, known as metabolism.
Christopher Forcados, Sandy Joaquina, Nicholas Paul Casey, Benjamin Caulier, Sébastien Wälchli   +4 more
doaj   +4 more sources

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice

Nature Communications, 2023
Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all.
Xiaomeng Hu, Karl Manner, Rowena DeJesus, Kathy White, Corie Gattis, Priscilla Ngo, Christopher Bandoro, Eleonore Tham, Elaine Y. Chu, Chi Young, Frank Wells, Ronald Basco, Annabelle Friera, Divy Kangeyan, Pascal Beauchesne, William E. Dowdle, Tobias Deuse, Terry J. Fry, Aaron E. Foster, Sonja Schrepfer   +19 more
doaj   +1 more source

Targeting chronic lymphocytic leukemia with B‐cell activating factor receptor CAR T cells

MedComm
The challenge of disease relapsed/refractory (R/R) remains a therapeutic hurdle in chimeric antigen receptor (CAR) T‐cell therapy, especially for hematological diseases, with chronic lymphocytic leukemia (CLL) being particularly resistant to CD19 CAR T ...
Yaqing Qie, Martha E. Gadd, Qing Shao, Tommy To, Andrew Liu, Shuhua Li, Rocio Rivera‐Valentin, Farah Yassine, Hemant S. Murthy, Roxana Dronca, Mohamed A. Kharfan‐Dabaja, Hong Qin, Yan Luo   +12 more
doaj   +1 more source

Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1

Molecular Therapy: Oncology
Chimeric antigen receptor (CAR) T cell therapy has encountered limited success in solid tumors. The lack of dependable antigens and the immunosuppressive tumor microenvironment (TME) are major challenges.
Yan Luo, Martha E. Gadd, Yaqing Qie, Andrea Otamendi-Lopez, Jesus E. Sanchez-Garavito, Mieu M. Brooks, Maria J. Ulloa Navas, Tanya Hundal, Shuhua Li, Vanessa K. Jones, Yanyan Lou, Tushar Patel, Roxana Dronca, Mohamed A. Kharfan-Dabaja, Haidong Dong, Alfredo Quinones-Hinojosa, Hong Qin   +16 more
doaj   +1 more source

Clinical trials of CAR-T cells in China

Journal of Hematology & Oncology, 2017
Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy.
Bingshan Liu, Yongping Song, Delong Liu
doaj   +1 more source

5G connected and automated driving: use cases, technologies and trials in cross-border environments

EURASIP Journal on Wireless Communications and Networking, 2021
Cooperative, connected and automated mobility (CCAM) across Europe requires harmonized solutions to support cross-border seamless operation. The possibility of providing CCAM services across European countries has an enormous innovative business ...
Dirk Hetzer, Maciej Muehleisen, Apostolos Kousaridas, Sokratis Barmpounakis, Stefan Wendt, Kurt Eckert, Andreas Schimpe, Johan Löfhede, Jesus Alonso-Zarate   +8 more
doaj   +1 more source

Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia

Chinese Medical Journal, 2020
. CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy is effective in refractory/relapsed (R/R) B-cell acute lymphoblastic leukemia (B-ALL). This review focuses on achievements, current obstacles, and future directions in CAR-T research.
Xian Zhang, Jing-Jing Li, Pei-Hua Lu, Peng Lyu   +3 more
doaj   +1 more source

TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss

Cancer Cell International, 2021
Background To investigate the effect of TriBAFF-CAR-T cells on hematological tumor cells. Methods TriBAFF-CAR-T and CD19-CAR-T cells were co-cultured with BAFFR-bearing B-cell malignancies at different effector/target ratios to evaluate the anti-tumor ...
Guangchao Li, Qing Zhang, Zhi Liu, Huijuan Shen, Yangmin Zhu, Zhao Zhou, Wen Ding, Siqi Han, Jie Zhou, Ruiming Ou, Min Luo, Shuang Liu   +11 more
doaj   +1 more source

Approved CAR-T therapies have reproducible efficacy and safety in clinical practice

Human Vaccines & Immunotherapeutics
CAR-T cell therapy has established itself as a highly effective treatment for hematological malignancies. There are currently six commercial CAR-T products that have been FDA approved for diseases such as B-ALL, LBCL, MCL, FL, MM, and CLL/SLL.
Daniel Goyco Vera, Hiral Waghela, Mohamed Nuh, Jonathan Pan, Premal Lulla   +4 more
doaj   +1 more source

Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells

Scientific Reports, 2022
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising novel therapeutic approach. However, primary and secondary resistance to CAR-T cell therapy is commonly encountered in various clinical trials. Despite the comprehensive studies to
Li Li, Qing Li, Zi-Xun Yan, Ling-Shuang Sheng, Di Fu, Pengpeng Xu, Li Wang, Wei-Li Zhao   +7 more
doaj   +1 more source